| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.098 | 0.06 |
| mRNA | TG-101348 | GDSC1000 | pan-cancer | AAC | 0.063 | 0.06 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.073 | 0.06 |
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | -0.077 | 0.06 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.075 | 0.06 |
| mRNA | BIBW2992 | FIMM | pan-cancer | AAC | 0.31 | 0.06 |
| mRNA | 16-beta-bromoandrosterone | CTRPv2 | pan-cancer | AAC | -0.083 | 0.06 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.06 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | 0.075 | 0.06 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.072 | 0.06 |